TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 466592
Drug: BCG (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG (120 mg) given orally
Study: 30704504
Drug: Transcranial pulsed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial pulsed electromagnetic fields (T-PEMF) treatment (30 min/day, 50 Hz, ±50 V, 3 ms squared pulses) for 8 weeks
Study: 30704504
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (sham stimulation, 30 min/day) for 8 weeks
Study: 30704504
Drug: Transcranial pulsed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial pulsed electromagnetic fields (T-PEMF) treatment
Study: 25518956
Drug: Nutritional support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional support including a family maize supplement provided to participants.
Study: 22307831
Drug: PEG‐IFN treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐IFN treatment
Study: 19391540
Drug: Prozac capsule,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prozac capsule, 20 mg/d
Study: 19391540
Drug: Electroacupuncture for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture for 30-40 min, needle retained for 1 h, once daily
Study: 19391540
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Prozac and electroacupuncture
Study: 12019085
Drug: Moxifloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin (400 mg i.v. once daily followed by oral 400 mg for 7 to 14 days)
Study: 12019085
Drug: Co-amoxiclav (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-amoxiclav (1.2 g i.v. three times a day followed by oral 625 mg three times a day, with or without clarithromycin)
Study: 7298924
Drug: Doxepin hydrochloride
Normalized name: Doxepin Hydrochloride
DrugBank: Doxepin (DB01142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxepin hydrochloride (5% solution)
Study: 7298924
Drug: Amitriptyline hydrochloride
Normalized name: Amitriptyline Hydrochloride
DrugBank: Amitriptyline (DB00321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amitriptyline hydrochloride (5% solution)
Study: 7298924
Drug: Diphenhydramine (5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenhydramine (5% solution)
Study: 25689529
Drug: Cotrimoxazole lock
Normalized name: Clotrimazole
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cotrimoxazole lock solution (10 mg/ml cotrimoxazole and 2500 U/ml heparin)
Study: 25689529
Drug: Heparin (2500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (2500 U/ml)
Study: 23134549
Drug: omega-3 polyunsaturated
Normalized name: omega-3 polyunsaturated fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: omega-3 polyunsaturated fatty acids (PUFAs) (3 g, 12 h before PCI) plus standard treatment (n = 43)
Study: 23134549
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (control group) (n = 47)
Study: 11146078
Drug: Intraperitoneal cisplatin-based
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraperitoneal cisplatin-based chemotherapy (IPCT) 100 mg/m²
Study: 11146078
Drug: Intravenous cisplatin-based
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous cisplatin-based chemotherapy (IVCT) 50 mg/m²
Study: 8282275
Drug: Monosodium L‐glutamate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monosodium L‐glutamate (MSG) doses of 1.5, 3.0 and 3.15 g/person
Study: 3552457
Drug: Alcoholic lignocaine
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcoholic lignocaine (5%) spray
Study: 3552457
Drug: Aqueous lignocaine
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous lignocaine (5%) spray
Study: 3552456
Drug: Aqueous cinchocaine
Normalized name: ethylcellulose aqueous dispersion type A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous cinchocaine (2%) spray
Study: 29286865
Drug: Adalimumab (ADA)
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab (ADA) with corticosteroids in a fixed tapering regime
Study: 19950239
Drug: Epoetin‐beta 30,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoetin‐beta 30,000 U administered s.c. q.w. (group A)
Study: 19950239
Drug: Reduced ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Reduced ribavirin dose of 600 mg daily (group B)
Study: 16190792
Drug: Sertraline (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (daily dose range between 25 and 100 mg)
Study: 7491646
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of dextroamphetamine orally every fourth day for 10 sessions paired with physical therapy
Study: 7491646
Drug: Placebo orally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo orally every fourth day for 10 sessions paired with physical therapy
Study: 1976487
Drug: Albuterol 200
Normalized name: ALBUTEROL 200MCG CAP,INHL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol 200 micrograms via MDI
Study: 7002949
Drug: Oral 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 0.1 N HCl
Study: 7002949
Drug: Oral 30
Normalized name: Aloral 300 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 30 g glucose
Study: 7002949
Drug: Oral glucose-acid
Normalized name: ascorbic acid / glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose-acid combination
Study: 7002949
Drug: Intraduodenal 20
Normalized name: ALCOHOL 80 mL in 100 mL INTRADUODENAL LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraduodenal 20 g glucose
Study: 7002949
Drug: Intraduodenal 75
Normalized name: ALCOHOL 80 mL in 100 mL INTRADUODENAL LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraduodenal 75 cc 0.1 N HCl
Study: 7002949
Drug: Intraduodenal glucose-acid
Normalized name: ascorbic acid / glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraduodenal glucose-acid combination
Study: 7002949
Drug: Oral glucose-acid
Normalized name: ascorbic acid / glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose-acid load
Study: 27680219
Drug: Standard/low dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard/low dose regimen starting at 70% of the minimal erythema dose (MED) with 20% dose increments
Study: 27680219
Drug: Medium dose
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium dose regimen starting at 200% MED with 25% increments
Study: 15823771
Drug: Lansoprazole 15
Normalized name: lansoprazole 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 15 mg sachet for suspension
Study: 15823771
Drug: Lansoprazole 15
Normalized name: lansoprazole 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 15 mg capsule
Study: 15823771
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg sachet for suspension
Study: 15823771
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg capsule
Study: 9466101
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL 0.5% plain bupivacaine
Study: 9466101
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL 0.9% saline with 5 mg diamorphine
Study: 9466101
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL 0.9% saline (control)
Study: 8180744
Drug: Picotamide (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Picotamide (1200 mg/day)
Study: 3286360
Drug: Colchicine 0.6
Normalized name: colchicine 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine 0.6 mg twice daily
Study: 31747236
Drug: FF/VI 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: FF/VI 100 mcg/25 mcg
Study: 26291137
Drug: FF 100
Normalized name: APAP 325/CAFF 100/ISOMETHEPTENE 65MG CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: FF 100 mcg
Study: 26445112
Drug: Glucagon +
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Glucagon + GLP-1 (same doses)
Study: 26445112
Drug: All peptide
Normalized name: Fibrin degradation agent, small peptide
Approvals — FDA: no, EMA: no, PMDA: no
Description: All peptide infusions
Study: 24019546
Drug: External beam
Normalized name: Beam
DrugBank: Tricyclazole (DB02891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: External beam radiation therapy (EBRT) following vaginal radium brachytherapy (n = 288)
Study: 22010012
Drug: S-1 (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 (80 to 120 mg per day for 4 weeks, followed by 2 weeks of rest, repeated for 1 year)
Study: 19564224
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment recommended by the Chilean Ministry of Health
Study: 16458130
Drug: downstream high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: downstream high-dose bolus tirofiban
Study: 15303805
Drug: Intra‐articular corticosteroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra‐articular corticosteroid injections (ICIs)
Study: 28385329
Drug: Benzathine penicillin
Normalized name: Benzathine penicillin G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzathine penicillin (BP) - 600,000 IU for children ≤27kg and 1,200,000 IU for children ≥27kg, administered every two weeks for six months.
Study: 28385329
Drug: Azithromycin (AZT)
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin (AZT) - 250mg for children ≤25kg and 500mg for children ≥25kg, administered once weekly for six months.
Study: 23233715
Drug: modified FOLFOX6
Approvals — FDA: no, EMA: no, PMDA: no
Description: modified FOLFOX6 plus bevacizumab (5 mg/kg) once every 2 weeks for 12 months
Study: 10429840
Drug: Zanamivir 10
Normalized name: Zanamivir 10 mg/mL solution for infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zanamivir 10 mg/day by oral inhalation for 28 days
Study: 7724714
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for major depression in primary care setting
Study: 1823578
Drug: Antioxidant compound
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant compound (2 tablets daily for 3 weeks)
Study: 7033994
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily dosage of carbamazepine (mean dose 13.9 mg/dg)
Study: 7033994
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily dosage of carbamazepine
Study: 7033994
Drug: Divided daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Divided daily doses of carbamazepine (2 to 3 times daily)
Study: 6145618
Drug: Pafenolol (beta-blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pafenolol (beta-blocker more beta 1-selective than metoprolol)
Study: 6145618
Drug: Prenalterol (selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenalterol (selective beta 1-stimulating agent)
Study: 23312051
Drug: n-3 PUFAs
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 PUFAs (3 g/day, 1 g three times a day during meals for 6 months)
Study: 22945778
Drug: Lubricant gel
Normalized name: Surgilube Lubricant Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lubricant gel
Study: 21966755
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens (CEE) 0.625 mg/day (group 1)
Study: 21966755
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens (CEE) 0.625 mg/day plus chlormadinone 1 mg/day (group 2)
Study: 12962026
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIg) administered every month or two months for more than half a year
Study: 9869584
Drug: 3-day regimen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-day regimen of oral azithromycin (500 mg/day for days 1 to 3)
Study: 9869584
Drug: 5-day regimen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-day regimen of oral azithromycin (500 mg on day 1 and 250 mg/day for days 2 to 5)
Study: 9869584
Drug: Both regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both regimens of oral azithromycin
Study: 30865288
Drug: Smartphone-based daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smartphone-based daily evaluation of mixed symptoms and irritability
Study: 30383906
Drug: nab-paclitaxel 100
Normalized name: paclitaxel 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nab-paclitaxel 100 mg/m2 on days 8 and 15 plus CC-486 200 mg daily on days 1 to 14
Study: 30383906
Drug: single-agent nab-paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: single-agent nab-paclitaxel 100 mg/m2 on days 1 and 8
Study: 27271664
Drug: 400 g
Normalized name: Ambi 60 PSE-400 GFN
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 g of olive fruit polyphenol-enriched yogurt with 50 mg of encapsulated olive polyphenols
Study: 27271664
Drug: 400 g
Normalized name: Ambi 60 PSE-400 GFN
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 g of plain yogurt
Study: 23485658
Drug: Preoperative education
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative education and administration of intramuscular diclofenac Na 75 mg regardless of pain reporting in the first two postoperative hours
Study: 23485658
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received no preoperative education and analgesics only upon pain reporting
Study: 21824010
Drug: ASCT treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASCT treatment (MPD plus RCT)
Study: 22933843
Drug: Integrated Treatment
Normalized name: Bag Spike + Integrated Clave
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated Treatment
Study: 16312171
Drug: 0.4% olopatadine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4% olopatadine nasal spray
Study: 16312171
Drug: 0.6% olopatadine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6% olopatadine nasal spray
Study: 16400902
Drug: Olopatadine nasal
Normalized name: olopatadine nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olopatadine nasal spray (0.4% and 0.6%)
Study: 9532321
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide nasal spray (42 mcg/nostril t.i.d.)
Study: 9532321
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide nasal spray (84 mcg/nostril t.i.d.)
Study: 3288292
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g pulsed methylprednisolone
Study: 3288292
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg pulsed methylprednisolone
Study: 3288292
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg pulsed methylprednisolone
Study: 12305415
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg dienestrol following each intercourse
Study: 12305415
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg dienestrol and 0.2 mg ethynodiol‐diacetate
Study: 19829284
Drug: 5-HT3 antagonists
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 5-HT3 antagonists
Study: 30684048
Drug: Neuroleptic antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuroleptic antipsychotics
Study: 25723472
Drug: Control (lopinavir/ritonavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (lopinavir/ritonavir with nucleoside/nucleotide reverse transcriptase inhibitors)
Study: 3530858
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg Acarbose with 100 g sucrose load
Study: 3530858
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with 100 g sucrose load
Study: 30328494
Drug: Oxytocin infusion
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin infusion (10 IU in 500 ml saline at 120 ml/h)
Study: 17473774
Drug: High-protein diet
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein diet (3.6 g.kg(‐1); HP)
Study: 17473774
Drug: Low-protein diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-protein diet (0.8 g.kg(‐1); LP)
Study: 17473774
Drug: Moderate-protein diet
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-protein diet (1.8 g.kg(‐1); MP)
Study: 15051932
Drug: AST-120 (6.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: AST-120 (6.0 g/day)
Study: 11576048
Drug: Remifentanil (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (0.5 microg x kg(‐1) x min(‐1)) combined with propofol (target plasma concentration of 1.5 microg x ml(‐1))
Study: 28081288
Drug: Short implants
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short implants (6 mm; GS/group short)
Study: 28081288
Drug: Long implants
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long implants (11-15 mm; GG/group graft)
Study: 25884448
Drug: 6 cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 cycles of neo‐adjuvant oxaliplatin‐based chemotherapy followed by surgery (arm B)
Study: 25884448
Drug: Surgery alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery alone (standard treatment, arm A)
Study: 3169371
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg standard release disopyramide given three times daily
Study: 3169371
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg sustained release disopyramide given twice daily
Study: 27110697
Drug: Sirukumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirukumab (10 mg/kg intravenously every 4 weeks through week 24)
Study: 19064574
Drug: Flaxseed-supplemented diet
Normalized name: FLAXSEED
DrugBank: Flax seed (DB10708)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed-supplemented diet (30 g/d)
Study: 14520146
Drug: Linezolid (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linezolid (10 mg/kg for patients <12 years; 600 mg for patients ≥12 years, intravenous/oral, 2-3 times daily)
Study: 7967990
Drug: Oral inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral inactivated whole-cell/recombinant-B-subunit cholera vaccine (WC/rBS)
Study: 3304929
Drug: ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ranitidine 300 mg at night + 200 mg ofloxacin twice daily
Study: 18650827
Drug: Sildenafil (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (50 or 100 mg) nightly for 36 weeks
Study: 8625230
Drug: PAM (cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAM (cisplatin 60 mg/m2 i.v. on Days 1 and 29; doxorubicin 30 mg/m2 i.v. on Days 1 and 29; mitomycin C 10 mg/m2 i.v. on Day 1; every 8 weeks)
Study: 8625230
Drug: FAM (5‐fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAM (5‐fluorouracil 600 mg/m2 i.v. on Days 1, 8, 29, 36; doxorubicin 30 mg/m2 i.v. on Days 1 and 29; mitomycin C 10 mg/m2 i.v. on Day 1; every 8 weeks)
Study: 27941065
Drug: Atorvastatin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (80 mg daily)
Study: 23631796
Drug: Inhaled glutathione
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled glutathione (646 mg in 4 ml) administered every 12 hours for 6 months
Study: 15837905
Drug: Brandt‐Daroff exercises
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brandt‐Daroff exercises (treatment group, n = 43)
Study: 15837905
Drug: No exercises
Approvals — FDA: no, EMA: no, PMDA: no
Description: No exercises (no-treatment group, n = 73)
Study: 15837905
Drug: Brandt‐Daroff exercises
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brandt‐Daroff exercises (treatment group)
Study: 15837905
Drug: No exercises
Approvals — FDA: no, EMA: no, PMDA: no
Description: No exercises (no-treatment group)
Study: 12898489
Drug: Pharmacy group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacy group (prescription for azithromycin to be filled at a local pharmacy)
Study: 10566643
Drug: Dietary soy
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary soy supplementation (60 g, 45 mg isoflavones)
Study: 8739813
Drug: Nicardipine 20
Normalized name: nicardipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine 20 mg tablet, three times daily for 3 months (TID group)
Study: 8739813
Drug: Slow release
Normalized name: Slow Release Iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow release nicardipine, 50 mg twice daily for 3 months (BID group)
Study: 7014726
Drug: new chromone
Approvals — FDA: no, EMA: no, PMDA: no
Description: new chromone compound
Study: 26871534
Drug: Negative hypnotic
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Negative hypnotic suggestions (based on the Pain Catastrophizing Scale)
Study: 26871534
Drug: Positive hypnotic
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Positive hypnotic suggestions (coping-oriented reversion of the Pain Catastrophizing Scale)
Study: 26871534
Drug: Neutral hypnotic
Normalized name: DentiCare Neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutral hypnotic suggestions (neutral sentence)
Study: 22709750
Drug: Medication management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication management intervention
Study: 15174784
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide treatment
Study: 15727381
Drug: Zolterol, SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolterol, SR (generic diclofenac sodium sustained release tablet)